Literature DB >> 20174891

Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.

Yoshikazu Ogawa1, Mika Watanabe, Teiji Tominaga.   

Abstract

Atypical adenoma has an aggressive biological character, invades the surrounding structures, and grows rapidly. Morphological malignant findings such as increasing cellularity and nuclear atypism are not involved in this entity, but some cases with overt malignant features such as significant nuclear atypism and/or necrosis are known. Null cell adenoma generally grows slowly, but hormone secretion is little understood. Atypical null cell adenoma is rare, and hormone production is unknown. A 55-year-old woman presented with severe hypopituitarism and diabetes insipidus and bilateral upper temporal quadrantanopsia. Head magnetic resonance imaging revealed a large sellar tumor compressing the optic chiasm. Transsphenoidal surgery was performed, but the tumor was partially removed because of invasion into the neuronal structures. Histological examination showed atypical null cell adenoma with significant nuclear atypism and extensive necrosis. Immunohistochemistry showed positive reaction to somatostatin. Adjuvant treatment was planned, but the tumor regrew within 3 months. Conventional irradiation resulted in slight decrease in tumor size, but she required assistance for every type of daily activity. Atypical null cell adenoma has an aggressive biological character, and immediate adjuvant treatment is essential. Somatostatin secretion was proven in this tumor type.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20174891     DOI: 10.1007/s12022-010-9110-2

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  24 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

2.  Ki67 cytoplasmic expression: observations in normal tissue from heart atrial appendages of healthy rats.

Authors:  Michele M Ciulla; Giulia Acquistapace; Laura Toffetti; Roberta Paliotti; Stefano Ferrero; Fabio Magrini; Paola Braidotti
Journal:  Cell Cycle       Date:  2009-07-18       Impact factor: 4.534

Review 3.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

4.  Chromosomal aberrations in pituitary carcinoma metastases.

Authors:  C H Rickert; B W Scheithauer; W Paulus
Journal:  Acta Neuropathol       Date:  2001-08       Impact factor: 17.088

Review 5.  Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report.

Authors:  M Sironi; G Cenacchi; L Cozzi; G Tonnarelli; M Iacobellis; D Treré; A Assi
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

6.  Sclerosing haemangioma of the lung is positive for MIB-1 in cell membrane and cytoplasmic staining pattern.

Authors:  H Hattori
Journal:  Histopathology       Date:  2002-03       Impact factor: 5.087

7.  A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment.

Authors:  Yoshikazu Ogawa; Teiji Tominaga
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

Review 8.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

9.  p53 gene mutations in pituitary adenomas: rare events.

Authors:  A Levy; L Hall; W A Yeudall; S L Lightman
Journal:  Clin Endocrinol (Oxf)       Date:  1994-12       Impact factor: 3.478

10.  Immunohistochemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas.

Authors:  Marek Pawlikowski; Hanna Pisarek; Jolanta Kunert-Radek; Andrzej Radek
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more
  1 in total

1.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.